{"id":"W2149095868","doi":"10.1200/jco.2008.18.4408","title":"Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Performance status; Clinical endpoint; Chemotherapy; Population; Adverse effect; Oncology; Gastroenterology; Cancer; Randomized controlled trial; Epidermal growth factor receptor; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003060434,0.002557965,0.005635652,0.0008157262,0.000638194,0.001374602,0.001492117,0.002916335,0.009462212],"category_scores_gemma":[0.003027366,0.001083574,0.002329754,0.0005777348,0.001949167,0.001591673,0.0005353423,0.003673353,0.001626247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111402,"about_ca_system_score_gemma":0.001677128,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009204211,"about_ca_topic_score_gemma":0.002311141,"domain_scores_codex":[0.9987112,0.0008179634,0.00006908942,0.0001820844,0.0000746829,0.000145069],"domain_scores_gemma":[0.9979565,0.0006428134,0.0004402501,0.0001532654,0.0001392812,0.0006677498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9833754,0.007080906,0.0003181138,0.0003092939,0.0005014439,0.00002413284,0.00002603722,0.000223182,0.00146227,0.00005657819,0.0003688739,0.006253802],"study_design_scores_gemma":[0.9572542,0.04160613,0.0004627932,0.000008322776,0.0001221459,0.00001346372,0.000007664829,0.0001575253,0.0001229294,0.00006219598,0.0001766924,0.00000598221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972351,0.005632557,0.001520663,0.001407116,0.001596374,0.01334727,0.001618024,0.000259481,0.002267553],"genre_scores_gemma":[0.974802,0.002537474,0.002358904,0.001763125,0.0007955187,0.01267829,0.001294257,0.00003848915,0.00373189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009462212,"threshold_uncertainty_score":0.03165424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03107094173745758,"score_gpt":0.4432891018328478,"score_spread":0.4122181600953903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}